IMNN
Imunon's Transformative Year: Groundbreaking IMNN-001 Results Set New Standard for Ovarian Cancer Treatment
Imunon, a pioneering biotechnology company, made history with its fourth quarter and full year 2025 financial results, showcasing a truly transformational year in the fight against ovarian cancer. The company's proprietary IL-12 immunotherapy, IMNN-001, has demonstrated unprecedented potential to redefine frontline treatment for women with newly diagnosed advanced